Utilization and Costs of Severe Uncontrolled Asthma in a Managed-Care Setting

Zeiger, Robert S.; Schatz, Michael; Dalal, Anand A.; Qian, Lei; Chen, Wansu; Ngor, Eunice W.; Suruki, Robert; Kawatkar, Aniket A.

doi:10.1016/j.jaip.2015.08.003

Cited by 136 publications

(87 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with severe asthma represent a major unmet need, as they experience frequent exacerbations, are hospitalized more often, and utilize the majority of health care expenses in asthma [3]. …”

Section: Introductionmentioning

confidence: 99%

Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults

Porsbjerg

Ulrik

Skjold

et al. 2018

European Clinical Respiratory Journal

View full text Add to dashboard Cite

Although a minority of asthma patients suffer from severe asthma, they represent a major clinical challenge in terms of poor symptom control despite high-dose treatment, risk of exacerbations, and side effects. Novel biological treatments may benefit patients with severe asthma, but are expensive, and are only effective in appropriately targeted patients. In some patients, symptoms are driven by other factors than asthma, and all patients with suspected severe asthma (‘difficult asthma’) should undergo systematic assessment, in order to differentiate between true severe asthma, and ‘difficult-to-treat’ patients, in whom poor control is related to factors such as poor adherence or co-morbidities. The Nordic Consensus Statement on severe asthma was developed by the Nordic Severe Asthma Network, consisting of members from Norway, Sweden, Finland, Denmark, Iceland and Estonia, including representatives from the respective national respiratory scientific societies with the aim to provide an overview and recommendations regarding the diagnosis, systematic assessment and management of severe asthma. Furthermore, the Consensus Statement proposes recommendations for the organization of severe asthma management in primary, secondary, and tertiary care.

show abstract

Section: Introductionmentioning

confidence: 99%

Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults

Porsbjerg

Ulrik

Skjold

et al. 2018

European Clinical Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…These patients with severe asthma are responsible for a relevant socioeconomic burden, in terms of direct costs related to out‐/inpatient treatments and indirect costs related to the quality of life worsening and work disability. These patients account for 50% of asthma total costs …”

Section: Introductionmentioning

confidence: 99%

RItA: The Italian severe/uncontrolled asthma registry

Maio

Baldacci

Bresciani

et al. 2017

Allergy

View full text Add to dashboard Cite

show abstract

“…A substantial proportion of the health care costs associated with asthma are related to hospitalisation, resulting from severe episodes referred to as acute exacerbations [2,3]. These exacerbations are most often triggered by respiratory viral infections, but may also result from acute exposure to high levels of allergens or ambient particulate matter [4][5][6].…”

mentioning

confidence: 99%

Enhanced Pro-Inflammatory Response of Macrophages to Interleukin-33 in an Allergic Environment

Chia

Kumar

Foster

et al. 2018

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Allergic asthma is common in childhood and is associated with a T-helper type 2 (Th2)-biased immunological response. Exacerbations of asthma are characterised by increased inflammation of the airways, which appears to be driven by interleukin (IL)-33 that can activate pulmonary macrophages. The Th2 cytokine environment of allergic asthma may contribute to exaggerated airway inflammation. Objectives: To test this, we assessed whether production of pro-inflammatory cytokines by IL-33-stimulated macrophages was enhanced in cells pre-treated with the key Th2 cytokines IL-4 and IL-13. We also investigated whether this was associated with altered expression of regulatory microRNAs (miRNAs). Methods: RAW264.7 cells cultured with IL-4 and IL-13 for 48 h were stimulated with IL-33 for 4 h. Pro-inflammatory mediators were assessed using quantitative real-time PCR (RT-PCR). Expression of miRNAs was assessed using microarrays and RT-PCR. In further experiments, we examined whether resolvin E1 (RvE1), which promotes the resolution of experimental asthmatic inflammation in vivo, could suppress the enhanced response by treating cells with RvE1 concurrently with IL-33 stimulation. Results: In cells pre-treated with IL-4 and IL-13, expression of mRNA for Ccl3, Ccl5, Ccl17, Ccl24, and Il1b in response to IL-33 stimulation was significantly increased. This was paralleled by up-regulated expression of miR-155-5p, a miRNA that is predicted to regulate several aspects of allergic inflammation. RvE1 suppressed the enhanced production of Ccl3, Ccl5, Ccl24, and Il1b. Conclusions: We conclude that IL-33-activated macrophages may contribute to the exaggerated airway inflammation in exacerbations of allergic asthma, and that RvE1 has potential as a therapeutic agent that targets macrophages.

show abstract

Utilization and Costs of Severe Uncontrolled Asthma in a Managed-Care Setting

Cited by 136 publications

References 33 publications

Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults

Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults

RItA: The Italian severe/uncontrolled asthma registry

Enhanced Pro-Inflammatory Response of Macrophages to Interleukin-33 in an Allergic Environment

Contact Info

Product

Resources

About